A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects

Inclusion Criteria: 1. Males aged 18 to 45; 2. Body Mass Index (BMI) is 19.0\~28.0 kg/m2, and body weight is 50.0\~80.0kg ; 3. Signing informed consent form before the trial and having a full understanding of the trial content, process and possible adverse reactions; 4. Able to complete the study according to the requirements of the study protocol. Exclusion Criteria: 1. Those with a history of digestive tract, respiratory, cardiovascular, endocrine, urinary, neurological, hematological, metabolic and other systemic diseases; 2. Those with a history of autoimmune diseases; 3. Those with a history of malignant tumor, unless it is a skin squamous cell carcinoma, basal cell carcinoma or cervical cancer in situ that has been successfully resected and has no evidence of metastasis; 4. Regular drinkers within 6 months prior to screening; 5. Those who are suspected or confirmed to be allergic or have had severe drug or food allergy reactions in the past, have a clear history of allergies and/or are allergic to the study drug or its components after inquiries; 6. Those who have used anti-PD-1/PD-L1 or/and anti-CTLA-4 drugs in the past; 7. Those who have been vaccinated with live or attenuated-live vaccines within 3 months before screening, or who are expected to receive vaccines during the study period; 8. Those who lost blood, donated blood or received any blood product transfusion of ≥400 ml within 3 months before screening; 9. Those who received major surgery or hospitalization due to illness within 3 months before screening; 10. Abnormal laboratory tests with clinical significance at screening; 11. Positive drug screening result; 12. Have a childbirth plan within 6 months from the screening period to the trial drug administration, or who are unwilling to take the contraceptive measures specified in the protocol during the trial period.